{
    "clinical_study": {
        "@rank": "53586", 
        "arm_group": {
            "arm_group_label": "S-1", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive chemoradiation with S-1.\nInterventions:\nDrug: S-1 Radiation: Radiation therapy"
        }, 
        "brief_summary": {
            "textblock": "This trial aims to study the safety, the local control, and the overall survival of S-1\n      combined with radiotherapy for patients with esophageal squamous cell carcinoma. 105\n      patients will be recruited into this trial."
        }, 
        "brief_title": "Study of S-1 in Combination With Radiotherapy in Esophageal Cancer", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Esophageal Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Esophageal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Joined the study voluntarily and signed informed consent form;\n\n          -  Age \uff1e75 or age 18-75 who are intolerant of or reject intravenous chemotherapy\n\n          -  Both genders\n\n          -  Esophageal squamous cell carcinoma confirmed by pathology\n\n          -  Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a,TxN1M0-1a,TxNxM1a,\n             AJCC 6th)\n\n          -  No radiotherapy, chemotherapy or other treatments prior to enrollment\n\n          -  PS ECOG 0-2\n\n          -  Life expectancy of more than 3 months\n\n          -  Hemoglobin\uff08Hb\uff09\u22659 g/dL\n\n          -  WBC\u22653x109/L, Neutrophils (ANC )\u22651.5x109/L\n\n          -  platelet count (Pt) \u2265100x 109/L\n\n          -  Hepatic function: ALAT and ASAT < 2.5 x ULN, TBIL<1.5 x ULN\n\n          -  Renal function: creatinine < 1.5 x ULN\n\n          -  No immuno-deficiency\n\n          -  Use of an effective contraceptive for adults to prevent pregnancy.\n\n        Exclusion Criteria:\n\n          -  Complete esophageal obstruction\n\n          -  Deep esophageal ulcer\n\n          -  Esophageal perforation\n\n          -  Haematemesis\n\n          -  After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting\n             therapy\n\n          -  Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma\n             in situ, who survived with no evidence disease for over 3 years\n\n          -  Participation in other interventional clinical trials within 30 days\n\n          -  Pregnant or breast-feeding women or people during the birth-period who refused to\n             take contraceptives\n\n          -  Drug addiction\n\n          -  Alcoholism or AIDS\n\n          -  Uncontrolled seizures or psychiatric diseases, loss of control over their own\n             behavior\n\n          -  Patient who has metastasis such as lung, liver metastasis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831531", 
            "org_study_id": "ESO2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "S-1", 
                "description": "S-1 40 mg (BSA \u2264 1.6 m2) or 50 mg (BSA >1.6 m2) p.o bid d1-28", 
                "intervention_name": "S-1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "S-1", 
                "description": "A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.", 
                "intervention_name": "Radiation therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 13, 2013", 
        "location": {
            "contact": {
                "email": "chenyun_qz@hotmail.com", 
                "last_name": "Yun Chen, M.M.", 
                "phone": "8621-64175590", 
                "phone_ext": "6726"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Kuaile Zhao, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yun Chen, M.M.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of S-1 in Combination With Radiotherapy in Esophageal Squamous Cell Carcinoma", 
        "overall_contact": {
            "email": "chenyun_qz@hotmail.com", 
            "last_name": "Yun Chen, M.M.", 
            "phone": "8621-64175590", 
            "phone_ext": "6726"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Kuaile Zhao, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "1-yr local control rate", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "2-yr local control rate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "3-yr local control rate", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831531"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Kuai Le Zhao, MD", 
            "investigator_title": "Professor of Radiation Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "1-yr overall survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "2-yr overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "3-yr overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}